Anastrozole - AstraZeneca

Drug Profile

Anastrozole - AstraZeneca

Alternative Names: Arimidex; ICI D 1033; ZD 1033

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Nitriles; Small molecules; Triazoles
  • Mechanism of Action Aromatase inhibitors; Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Discontinued Female infertility

Most Recent Events

  • 01 Apr 2016 AstraZeneca completes the DATA phase III trial in Breast cancer (Adjuvant therapy) in Netherlands (NCT00301457)
  • 15 Mar 2016 Biomarkers information updated
  • 19 Mar 2015 Launched for Breast cancer in Canada, Greece, Hungary, Finland, Sweden, Switzerland, Poland, Venezuela, Chile, China, Hong Kong, Philippines, Malaysia, Indonesia, Russia, Ukraine, Turkey, Israel,Bolivia, Ecuador, Dominican Republic, Costa Rica, Colombia, El Salvador, Guyana, Guatemala, Honduras, Peru, Paraguay, Panama, Nicaragua, Uruguay, Netherlands Antilles, Bahamas, Bermuda, Jamaica, Trinidad and Tobago, Croatia, Bulgaria, Estonia, Lithuania, Latvia, Romania, Slovenia, Iceland, Bosnia-Herzegovina, Belarus, Serbia, Georgia, Kazakhstan, Pakistan, United Arab Emirates, Bahrain, Egypt, Tunisia, Jordan, Iran, Iraq, Lebanon, Kuwait, Saudi Arabia, Oman, Syria, Yemen, Cambodia, Taiwan, South Korea, Vietnam, Kenya and India (PO) before March 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top